A Phase 3 interventional study of Icatibant and Tranexamic Acid in Hereditary Angioedema, sponsored by Shire. Completed at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-06-09.
Sponsored by Shire (part of Takeda) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing icatibant in Angioedemas, Hereditary — none open to participants now, none under way, none of them phase 3. icatibant · Angioedemas, Hereditary.
Among the 10 studies testing icatibant in Angioedemas, Hereditary, this one is the 3rd largest by enrollment, is the only one that started in 2005, is one of 7 in phase 3, and was the 2nd registered.
171 studies on the registry are indexed under Angioedemas, Hereditary; 24 are open to participants now.
Browse Angioedemas, Hereditary studies →None of the 10 studies testing icatibant in Angioedemas, Hereditary is open now. The open studies under Angioedemas, Hereditary, anywhere →
icatibant: first FDA approval 2011 (FIRAZYR), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 13 Angioedemas, Hereditary studies recruiting now, 9 (69%) set no upper age limit and 4 (31%) stop at 75 or younger; 7 take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2005.
This study's enrollment of 85 is above the median of 48 across 116 interventional studies indexed under Angioedemas, Hereditary.
Median enrollment 26 across the 10 interventional studies. Of the 10 that completed or were terminated, 9 (90%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 10 have an industry lead sponsor. The 4 most frequent:
This study is registered under Shire, one of the names counted as Takeda. Under that name alone:
Shire is the lead sponsor of 351 studies on the registry; 2 are open to participants now.
Of its 48 completed or terminated interventional studies of FDA-regulated products, 48 (100%) have results posted.
58 studies in Angioedemas, Hereditary by Takeda: 3 open now, 4 under way, none of them phase 3. Of 52 finished, 33 (63%) have results posted.
Among the 58 studies in Angioedemas, Hereditary by Takeda, this one is the 11th largest by enrollment of the 36 interventional ones that give a count, is one of 4 that started in 2005, is one of 23 in phase 3, and was the 9th registered.
Takeda’s Angioedemas, Hereditary studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing icatibant in Angioedemas, Hereditary, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Takeda’s 58 in Angioedemas, Hereditary:
This tab as a report to print or save as PDF → With an account.
Primary Outcome Measures:
The primary endpoint was the time to onset of symptom relief of the first attack in the double blind phase. H0: λ icatibant/λ tranexamic acid =1 versus H1: λ icatibant/λ tranexamic acid ≠1 Where: λ icatibant refers to the hazard rate under icatibant and λ tranexamic acid refers to the hazard rate under tranexamic acid.
Secondary Outcome Measures:
This was a Phase III, randomised, double blind, double dummy, multicentre, controlled,parallel group study of a 30 mg s.c. formulation of icatibant for the treatment of patients with moderate to very severe symptoms of cutaneous and/or abdominal symptoms of HAE.
The study consisted of two parts: controlled phase and OLE phase. For the primary endpoint, Efficacy was determined by evaluating the differences in study outcomes using a Visual Analogue Scale for patients treated with icatibant and tranexamic acid.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects received S.C icatibant+ oral placebo Icatibant Form: solution for injection, 3 mL, 10 mg/mL Single dose: 30 mg (3 mL) Placebo Form: hard capsule Single dose: 2 capsules Frequency: 3 x 2 capsules for 2 days, taken orally, 6 to 8 hours apart
Drug: Icatibant · Drug: Oral Placebo
Subjects received oral Tranexamic acid+ S.C. placebo Tranexamic acid Form: over encapsulated film tablet Single dose: 1000 mg (2 capsules) Frequency: 3 x 2 capsules for 2 days, taken orally, 6 to 8 hours apart Placebo Form: solution for injection, matched to icatibant for injection Single dose: 3 mL Frequency: one subcutaneous injection in the abdominal region
Drug: Tranexamic Acid · Drug: S.C. Placebo
Patients with laryngeal symptoms at the baseline were not randomised but treated with icatibant open label during the controlled phase.
Drug: Icatibant
Patients who were screened and found eligible but did not experience an angioedema attack, or had an attack that was not severe enough to merit treatment while the controlled phase was ongoing were treated in the open label phase with icatibant
Drug: Icatibant
Icatibant: a stable, synthetic decapeptide and specific BK B2 receptor antagonist.
Also known as: Brand name, Firazyr®
over encapsulated film tablet an anti-fibrinolytic agent,is used in some European countries for the treatment of acute oedema episodes and the continuous prophylaxis of HAE.
hard capsule matched to tranexamic acid
Also known as: Placebo
solution for injection, matched to icatibant for injection
Also known as: Placebo
Time to Onset of Symptom Relief.
The primary efficacy endpoint was Time to onset of symptom relief (TOSR) following treatment with either icatibant or tranexamic acid. The median time to onset of symptom relief for the icatibant group was compared to the the median time to onset of symptom relief for the tranexamic acid group. TOSR was defined as the time between time of injection to time of first documented onset of symptom relief for the three primary symptoms: cutaneous swelling, cutaneous skin, and abdominal pain. The primary symptom was based on the type of attack. For abdominal attacks, the single primary symptom was abdominal pain. For cutaneous attacks, the single primary symptom was either skin swelling or skin pain, whichever was most severe.
Time frame: 2 days
Time to Almost Complete Symptom Relief
Almost complete symptom relief was defined as a score between 0 and 10 mm on the VAS for at least three consecutive measurements for all symptoms.
Time frame: 48 hours
| Milestone | Randomized Controlled -Icatibant | Randomized Controlled-Tranexamic Acid | Controlled Open-label / Laryngeal Attack | Untreated Patients at the Baseline |
|---|---|---|---|---|
| Started | 36 | 38 | 3 | 8 |
| Completed | 26 | 28 | 2 | 0 |
| Not completed | 10 | 10 | 1 | 8 |
| Milestone | Randomized Controlled -Icatibant | Randomized Controlled-Tranexamic Acid | Controlled Open-label / Laryngeal Attack | Untreated Patients at the Baseline |
|---|---|---|---|---|
| Started | 23 | 21 | 2 | 8 |
| Completed | 16 | 9 | 1 | 6 |
| Not completed | 7 | 12 | 1 | 2 |
The primary efficacy endpoint was Time to onset of symptom relief (TOSR) following treatment with either icatibant or tranexamic acid. The median time to onset of symptom relief for the icatibant group was compared to the the median time to onset of symptom relief for the tranexamic acid group. TOSR was defined as the time between time of injection to time of first documented onset of symptom relief for the three primary symptoms: cutaneous swelling, cutaneous skin, and abdominal pain. The primary symptom was based on the type of attack. For abdominal attacks, the single primary symptom was abdominal pain. For cutaneous attacks, the single primary symptom was either skin swelling or skin pain, whichever was most severe.
| Hours | Randomized Controlled -Icatibant | Randomized Controlled-Tranexamic Acid |
|---|---|---|
| Time to Onset of Symptom Relief. | 2.0 (1.0 to 3.5) | 12.0 (3.5 to 25.4) |
Almost complete symptom relief was defined as a score between 0 and 10 mm on the VAS for at least three consecutive measurements for all symptoms.
| Hours | Randomized Controlled -Icatibant | Randomized Controlled-Tranexamic Acid |
|---|---|---|
| Time to Almost Complete Symptom Relief | 10.0 (2.8 to 23.2) | 51.0 (12.0 to 79.5) |
Collected over An AE was assigned to the controlled phase if the start date of the event was between the first treatment of the first attack and the first treatment in the OLE phase.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Controlled Phase- Icatibant (Randomized Subjects ) | — | 4/36 (11.1%) | 19/36 (52.8%) |
| Controlled Phase- Tranexamic Acid (Randomized Subjects) | — | 1/38 (2.6%) | 16/38 (42.1%) |
| Controlled Phase- Icatibant (Subjects w/ Laryngeal Attack) | — | 1/3 (33.3%) | 1/3 (33.3%) |
| Open Label Extension Phase- Icatibant (Previously Randomized) | — | 9/44 (20.5%) | 31/44 (70.5%) |
| Open Label Extension Phase (Subjects w/ Laryngeal Attack) | — | 1/2 (50%) | 1/2 (50%) |
| Open Label Extension Phase(Untreated Patients at the Baseline | — | 0/8 (0%) | 4/8 (50%) |
| Event | Controlled Phase- Icatibant (Randomized Subjects ) | Controlled Phase- Tranexamic Acid (Randomized Subjects) | Controlled Phase- Icatibant (Subjects w/ Laryngeal Attack) | Open Label Extension Phase- Icatibant (Previously Randomized) | Open Label Extension Phase (Subjects w/ Laryngeal Attack) | Open Label Extension Phase(Untreated Patients at the Baseline |
|---|---|---|---|---|---|---|
| Hereditary AngioedemaCongenital, familial and genetic disorders | 2/36 | 0/38 | 1/3 | 3/44 | 1/2 | 0/8 |
| GastroenteritisInfections and infestations | 1/36 | 0/38 | 0/3 | 2/44 | 0/2 | 0/8 |
| CholelithiasisHepatobiliary disorders | 1/36 | 0/38 | 0/3 | 0/44 | 0/2 | 0/8 |
| CystitisInfections and infestations | 1/36 | 0/38 | 0/3 | 0/44 | 0/2 | 0/8 |
| Hypertensive CrisisVascular disorders | 1/36 | 0/38 | 0/3 | 0/44 | 0/2 | 0/8 |
| Aortic Value SclerosisCardiac disorders | 0/36 | 1/38 | 0/3 | 0/44 | 0/2 | 0/8 |
| Sudden Cardiac DeathGeneral disorders | 0/36 | 1/38 | 0/3 | 0/44 | 0/2 | 0/8 |
| Coronary Artery DiseaseCardiac disorders | 0/36 | 0/38 | 0/3 | 1/44 | 0/2 | 0/8 |
| Head InjuryInjury, poisoning and procedural complications | 0/36 | 0/38 | 0/3 | 1/44 | 0/2 | 0/8 |
| Road Traffic AccidentInjury, poisoning and procedural complications | 0/36 | 0/38 | 0/3 | 1/44 | 0/2 | 0/8 |
| Event | Controlled Phase- Icatibant (Randomized Subjects ) | Controlled Phase- Tranexamic Acid (Randomized Subjects) | Controlled Phase- Icatibant (Subjects w/ Laryngeal Attack) | Open Label Extension Phase- Icatibant (Previously Randomized) | Open Label Extension Phase (Subjects w/ Laryngeal Attack) | Open Label Extension Phase(Untreated Patients at the Baseline |
|---|---|---|---|---|---|---|
| Hereditary AngioedemaCongenital, familial and genetic disorders | 10/36 | 6/38 | 1/3 | 10/44 | 1/2 | 1/8 |
| Gingival InfectionInfections and infestations | 0/36 | 0/38 | 0/3 | 0/44 | 1/2 | 0/8 |
| Urinary Track InfectionInfections and infestations | 0/36 | 0/38 | 0/3 | 6/44 | 0/2 | 0/8 |
| Dental CariesInfections and infestations | 0/36 | 0/38 | 0/3 | 0/44 | 0/2 | 1/8 |
| Respiratory Track InfectionInfections and infestations | 0/36 | 0/38 | 0/3 | 1/44 | 0/2 | 1/8 |
| DizzinessNervous system disorders | 0/36 | 0/38 | 0/3 | 0/44 | 0/2 | 1/8 |
| PruritusSkin and subcutaneous tissue disorders | 0/36 | 0/38 | 0/3 | 0/44 | 0/2 | 1/8 |
| Dental OperationSurgical and medical procedures | 0/36 | 0/38 | 0/3 | 0/44 | 0/2 | 1/8 |
| NasopharyngitisInfections and infestations | 2/36 | 3/38 | 0/3 | 4/44 | 0/2 | 0/8 |
| Injury, poisoning and procedual complicationsInjury, poisoning and procedural complications | 3/36 | 1/38 | 0/3 | 3/44 | 0/2 | 0/8 |
| Age, Continuous(years) | Randomized Controlled -Icatibant | Randomized Controlled-Tranexamic Acid | Controlled Open-label / Laryngeal Attack | Untreated Patients at the Baseline | Total |
|---|---|---|---|---|---|
| Mean | 40.4 ± 13.59 | 41.9 ± 12.36 | 35.0 ± 11.36 | 40.6 ± 13.51 | 40.9 ± 12.8 |
| Sex: Female, Male(Participants) | Randomized Controlled -Icatibant | Randomized Controlled-Tranexamic Acid | Controlled Open-label / Laryngeal Attack | Untreated Patients at the Baseline | Total |
|---|---|---|---|---|---|
| Female | 24 | 23 | 1 | 7 | 55 |
| Male | 12 | 15 | 2 | 1 | 30 |
| Region of Enrollment(Participants) | Randomized Controlled -Icatibant | Randomized Controlled-Tranexamic Acid | Controlled Open-label / Laryngeal Attack | Untreated Patients at the Baseline | Total |
|---|---|---|---|---|---|
| Austria | 3 | 4 | 0 | 1 | 8 |
| France | 3 | 1 | 0 | 2 | 6 |
| Germany | 13 | 12 | 0 | 0 | 25 |
| Hungary | 3 | 3 | 0 | 0 | 6 |
| Ireland | 0 | 1 | 0 | 0 | 1 |
| Israel | 4 | 4 | 3 | 4 | 15 |
| Italy | 3 | 5 | 0 | 1 | 9 |
| Lithuania | 1 | 2 | 0 | 0 | 3 |
| Poland | 1 | 2 | 0 | 0 | 3 |
| Sweden | 3 | 2 | 0 | 0 | 5 |
| Switzerland | 2 | 2 | 0 | 0 | 4 |
Ran from Mar 2005 to primary completion in Jul 2006, 16 months.
Results were first posted in Jun 2014, 7 years 10 months after primary completion.
Of 46 industry-sponsored phase 3 interventional studies under Angioedemas, Hereditary, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 33. This study's 16 months is below that.
Counting every sponsor, half of 46 studies reached it within 22 months; a quarter within 16 and three quarters within 33.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Icatibant